A recent clinical study showed that the SGLT2 inhibitor empagliflozin did not alter euvolemic fluid status for 24 weeks (ECW/TBW: baseline 0.392 and 24 weeks 0.391, p = 0.460) in patients with acute myocardial infarction and type 2 diabetes mellitus (47). This evidence concerns the gene SLC5A2 and diabetes mellitus.